Citations

Clear

585 citation(s) found for "Tran, Ha".

American College of Clinical Pharmacy Global Health Practice and Research Network's opinion paper: Pillars for global health engagement and key engagement strategies for pharmacists
Crowe, Susie , Schellhase, Ellen , Miller, Monica L. , Abrons, Jeanine P., Alsharif, Naser Z., Andrade, Christina , Cope, Rebecca , Dornblaser, Emily K., Hachey, David M. , Holm, Michelle R., Jonkman, Lauren , Lukas, Stephanie , Malhotra, Jodie , Njuguna, Benson , Pekny, Chelsea, Prescott, Gina M. , Steeb, David R. , Tran, Dan N. , Karwa, Rakhi , Ryan, Melody A.

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | March 31, 2020 | Volume: 3 | Issue: 6 | Pages: 1097-1112

10.1002/jac5.1232 Get It

AbstractThe scope of pharmacy practice in global health has expanded over the past decade creating additional education and training opportunities for students, residents and pharmacists. There has also been a shift from short‐term educational and clinical experiences to more sustainable bidirectional partnerships between high‐income countries (HICs) and low‐ to middle‐income countries (LMICs). As more institutional and individual partnerships between HICs and LMICs begin to form, it is clear that there is a lack of guidance for pharmacists on how to build meaningful, sustainable, and mutually beneficial programs. The aim of this paper is to provide guidance for pharmacists in HICs to make informed decisions on global health partnerships and identify opportunities for engagement in LMICs that yield mutually beneficial collaborations. This paper uses the foundations of global health principles to identify five pillars of global health engagement when developing partnerships: (a) sustainability, (b) shared leadership, (c) mutually beneficial partnerships, (d) local needs‐based care and (e) host‐driven experiential and didactic education. Finally, this paper highlights ways pharmacists can use the pillars as a framework to engage and support health care systems, collaborate with academic institutions, conduct research, and interface with governments to improve health policy.
Global, Regional, and National Burden of Calcific Aortic Valve and Degenerative Mitral Valve Diseases, 1990–2017
Yadgir, Simon , Johnson, Catherine O., Aboyans, Victor, Adebayo, Oladimeji , Adedoyin, Rufus Adesoji , Afarideh, Mohsen , Alahdab, Fares , Alashi, Alaa , Alipour, Vahid, Arabloo, Jalal , Azari, Samad , Barthelemy, Celine M, Benziger, Catherine P. , Bijani, Ali , Carvalho, Félix , Durães, André Rodrigues , Esteghamati, Alireza , Farid, Talha, Farzadfar, Farshad , Fernandes, Eduarda , Gad, Mohamed M. , Hay, Simon I , Irvani, Seyed Sina Naghibi , Jürisson, Mikk , Kasaeian, Amir , Kengne, André Pascal , Khan, Abdur Rahman , Kısa, Adnan , Manafi, Navid , Manafi, Amir , Мirrakhimov, Erkin М , Mohammad, Yousef , Mokdad, Ali H. , Negoi, Ruxandra Irina , Nixon, Molly R, Patel, Shanti, Pilgrim, Thomas , Rawaf, David Laith , Rawasia, Wasiq Faraz , Rezapour, Aziz , Roever, Leonardo , Saadatagah, Seyedmohammad , Senthilkumaran, Subramanian , Sliwa, Karen, Tesfay, Berhe Etsay , Ullah, Irfan , Roth, Gregory A. , Collaborators, For the Global Burden of Disease Study 2017 Nonrheumatic Valve Disease, Sliwa, Karen , Farzadfar, Farshad , Benziger, Catherine P , Sliwa, K , Pilgrim, Thomas , Aboyans, Victor , Berman, Adam E. , Carrero, Juan Jesús , Daryani, Ahmad , Filip, Irina , Hamidi, Samer , Ilesanmi, Olayinka Stephen , Kısa, Sezer , Kolte, Dhaval , Mensah, George A. , Nguyen, Huong Lan Thi , Nguyen, Trang Huyen , Otto, Catherine M , Radfar, Amir , Rawaf, Salman , Saad, Anas M. , Tran, Bach Xuan , Vaduganathan, Muthiah , Vasankari, Tommi Juhani , Wolfe, Charles D.A. , Yonemoto, Naohiro , Collaborators, For the Global Burden of Disease Study 2017 Nonrheumatic Valve Disease, Alahdab, Fares

Mayo Clinic

Circulation | March 29, 2020 | Volume: 141 | Issue: 21 | Pages: 1670-1680

10.1161/circulationaha.119.043391 | PMID 32223336 Get It

Background: Nonrheumatic valvular diseases are common; however, no studies have estimated their global or national burden. As part of the Global Burden of Disease Study 2017, mortality, prevalence, and disability-adjusted life-years (DALYs) for calcific aortic valve disease (CAVD), degenerative mitral valve disease, and other nonrheumatic valvular diseases were estimated for 195 countries and territories from 1990 to 2017. Methods: Vital registration data, epidemiologic survey data, and administrative hospital data were used to estimate disease burden using the Global Burden of Disease Study modeling framework, which ensures comparability across locations. Geospatial statistical methods were used to estimate disease for all countries, because data on nonrheumatic valvular diseases are extremely limited for some regions of the world, such as Sub-Saharan Africa and South Asia. Results accounted for estimated level of disease severity as well as the estimated availability of valve repair or replacement procedures. DALYs and other measures of health-related burden were generated for both sexes and each 5-year age group, location, and year from 1990 to 2017. Results: Globally, CAVD and degenerative mitral valve disease caused 102 700 (95% uncertainty interval [UI], 82 700–107 900) and 35 700 (95% UI, 30 500–42 500) deaths, and 12.6 million (95% UI, 11.4 million–13.8 million) and 18.1 million (95% UI, 17.6 million–18.6 million) prevalent cases existed in 2017, respectively. A total of 2.5 million (95% UI, 2.3 million–2.8 million) DALYs were estimated as caused by nonrheumatic valvular diseases globally, representing 0.10% (95% UI, 0.09%–0.11%) of total lost health from all diseases in 2017. The number of DALYs increased for CAVD and degenerative mitral valve disease between 1990 and 2017 by 101% (95% UI, 79%–117%) and 35% (95% UI, 23%–47%), respectively. There is significant geographic variation in the prevalence, mortality rate, and overall burden of these diseases, with highest age-standardized DALY rates of CAVD estimated for high-income countries. Conclusions: These global and national estimates demonstrate that CAVD and degenerative mitral valve disease are important causes of disease burden among older adults. Efforts to clarify modifiable risk factors and improve access to valve interventions are necessary if progress is to be made toward reducing, and eventually eliminating, the burden of these highly treatable diseases.
Abstract PR10: Enhancing the effect of autophagy inhibition for pancreatic cancer treatment
Lee, Ye S. , Grover, Kajal R., Edwards, A. Cole , Peng, Sen, Petricoin, Emanuel F. , Tran, Nhan L. , Kimmelman, Alec C. , Tran, Nhan L , Bryant, Kirsten L. , Klomp, Jennifer E. , Stalnecker, Clint A. , Pierobon, Mariaelena , Cox, Adrienne D. , Der, Channing J

Mayo Clinic

Cancer Research | March 26, 2020 | Volume: 79 | Issue: 24_Supplement | Pages: PR10-PR10

10.1158/1538-7445.panca19-pr10 Get It

Abstract Pancreatic ductal adenocarcinoma (PDAC) is characterized by KRAS- and autophagy-dependent tumorigenic growth. We determined the role of mutationally activated KRAS, found in ~95% of PDAC, in supporting autophagy. Surprisingly, acute KRAS suppression, which blocks proliferation, was associated with increased rather than decreased autophagic flux. Pharmacologic inhibition of ERK MAPK phenocopied the genetic silencing of KRAS and also increased autophagic flux. We speculated that the loss of ERK-driven metabolic processes may induce compensatory mechanisms to increase autophagy. Addressing a mechanism for ERK suppression-increased autophagy, we describe three mechanisms: 1) ERK inhibition-mediated increased transcription of autophagy and lysosomal genes, 2) ERK inhibitor-induced AMPK activation and suppression of mTOR signaling, and 3) ERK inhibition-facilitated decreased glycolytic flux. We then addressed whether ERK inhibition increased PDAC dependence on autophagy. Supporting this possibility, we found that cotreatment with the autophagy inhibitor chloroquine (CQ) synergistically enhanced ERK inhibitor-mediated antiproliferative activity. Similarly, genetic or pharmacologic inhibition of specific regulators of autophagy also enhanced ERK inhibitor activity. Encouraged by the synergistic relationship between ERK and autophagy inhibition, we performed a CRISPR/Cas-9 mediated genetic loss of function screen in the presence of CQ to determine additional sensitizers as well as mediators of resistance to autophagy inhibition. Top sensitizers included multiple mediators of the DNA damage response. One such sensitizing gene was CHEK1, which encodes the CHK1 serine/threonine kinase, required for checkpoint-mediated cell cycle arrest and activation of DNA repair in response to DNA damage. Accordingly, we showed that treatment with prexasertib, a clinical candidate CHK1 inhibitor, increased autophagic flux in PDAC cells and synergized with CQ to decrease PDAC cell proliferation and increase apoptosis. We conclude that concurrent suppression of multiple metabolic processes, to block compensatory rebound activities, will be needed for effective PDAC treatment. This abstract is also being presented as Poster B07. Citation Format: Kirsten L. Bryant, Jennifer E. Klomp, Ye S. Lee, Clint A. Stalnecker, Kajal R. Grover, A. Cole Edwards, Sen Peng, Mariaelena Pierobon, Emanuel F. Petricoin III, Nhan Tran, Alec C. Kimmelman, Adrienne D. Cox, Channing J. Der. Enhancing the effect of autophagy inhibition for pancreatic cancer treatment [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2019 Sept 6-9; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2019;79(24 Suppl):Abstract nr PR10.
Do We Publish What We Present? A Critical Analysis of Abstracts Presented at Three Plastic Surgery Meetings
Rajesh, Aashish , Tarabishi, Ahmad Sankari, Sakkal, Najeeb, Banuelos, Joseph, Vyas, Krishna S. , Tran, Nho V. , Tarabishi, Ahmad S, Asaad, Malke

Mayo Clinic

Plastic & Reconstructive Surgery | March 20, 2020 | Volume: 145 | Issue: 6 | Pages: 1555-1564

10.1097/prs.0000000000006849 | PMID 32205543 Get It

Background: Presentation of research at scientific conferences provides an opportunity for researchers to disseminate their work and gain peer feedback. However, much of the presented work is never published in peer-reviewed journals. The authors analyzed the conversion rate of abstracts presented at three national plastic surgery meetings. Methods: Abstracts presented at the American Association of Plastic Surgeons (AAPS), the American Society of Plastic Surgeons (ASPS), and the Plastic Surgery Research Council (PSRC) annual meetings in 2014 and 2015 were identified to analyze the rates of successful conversion into full-text publications. Meeting administrators were contacted to obtain the respective acceptance rates of submitted abstracts. Results: A total of 1174 abstracts were analyzed. The overall conversion rate was 65 percent. The AAPS meeting had the highest conversion rate (73 percent), followed by the PSRC (66 percent) and the ASPS (61 percent). Conversely, the AAPS meeting had a lower acceptance rate (28 percent) compared with the ASPS (42 percent) and PSRC (49 percent) meetings. The conversion rate was significantly higher for abstracts from native English-speaking countries, whereas no significant differences were noted between oral and poster presentations. Plastic and Reconstructive Surgery had the highest percentage of published manuscripts (34 percent). Abstracts presented at the PSRC meeting had the highest mean impact factor for the journal of publication. First authors changed in 31 percent and last authors changed in 18 percent of publications. The overall median time to publication from the date of presentation was 13 months. Conclusions: Almost two-thirds of abstracts presented at AAPS, ASPS, and PSRC meetings successfully converted into full-text publications. Plastic surgery departments/divisions should follow unpublished work in their institutions to benefit both patients and the scientific community.
511 Point-of-care 3-dimensional Body Mapping for Determining Total Body Surface Area in Severely Burned Patients
Loegering, Julia, Webb, Kevin, Ahlquist, Jesse , Krause, Kevin, Xu, Karen , Palmieri, Tina L. , Webb, Kevin L., Greenhalgh, David G. , Tran, Nam K

Mayo Clinic

Journal of Burn Care & Research | March 4, 2020 | Volume: 41 | Issue: Supplement_1 | Pages: S92-S93

10.1093/jbcr/iraa024.143 Get It

Abstract Introduction With severe burn injury, there is systemic fluid loss due to inflammatory responses in damaged tissue, leading to disruption of cellular processes. Patient fluid levels are restored with the calculation of total body surface area (TBSA). Clinically used TBSA equations are often outdated and inaccurate with error up to 20%, resulting in misinformed treatment and subsequent sequelae including prolonged hospital length of stay and increased mortality. Our objective, therefore, was to create a point-of-care (POC) system employing 3D imaging technology to accurately calculate TBSA for all patient population varieties. Methods Our team employed an iPad attachable, infrared scanner to create 3D models of the human body. From these models, TBSA can be extrapolated using scan processing software. Subject scans were collected on our device and on a gold standard scanner for comparison of TBSA output. Clinical testing on burn patients is occurring at present to establish scanning precision of TBSA in the burn care environment. Results Non-clinical verification tests of the 3D scanned TBSA revealed a 4.05% error when compared to the gold standard, and precision error of 3.8%. Additionally, we introduced the device into the burn unit for preliminary testing with a physician user and non-patient subjects. The subjects were scanned in a prone position to mimic burn care workflow. Clinician scanning error was 1.41% when compared to the gold standard scan of the same subject. Clinical precision study results are on-going in collection. Conclusions Our device introduces an improved method of TBSA estimation to assist clinicians in making accurate burn care decisions and further precision medicine with greater anthropomteric data, notably for children. This device is one of the first POC-3D scanning technologies to be used in a burn setting and may also be employed at outlying medical facilities. Destructive wildfires and combat burn injuries highlight the need for such a device to standardize the triage of burn victims with and away from experienced medical staff. Applicability of Research to Practice 3D body mapping points to an enhanced method of TBSA calculation and minimally disruptive to the burn workflow. Future developments of 3D scanning include deep learning algorithms to identify and better assess burned surface area. Additionally, further automation of TBSA scan processing to reduce user error in calculation and improve burn injury outcomes.
Association of black race with improved outcomes following definitive radiotherapy with androgen deprivation therapy for high-risk prostate cancer: A meta-analysis of eight randomized trials.
Kishan, Amar U. , Romero, Tahmineh , Garraway, Isla P. , Roach, Mack , Pisansky, Thomas M. , Michalski, Jeff M. , Jones, Christopher U. , Feng, Felix Y. , Nickols, Nicholas G. , Mahal, Brandon A. , Dess, Robert T. , Steinberg, Michael L. , Elashoff, David , Dess, Robert T , Rettig, Matthew B. , Lee, W. Robert , Rosenthal, Seth A. , Boutros, Paul C. , Tran, Phuoc T , Sandler, Howard M. , Spratt, Daniel E.

Mayo Clinic

Journal of Clinical Oncology | February 19, 2020 | Volume: 38 | Issue: 6_suppl | Pages: 327-327

10.1200/jco.2020.38.6_suppl.327 Get It

327 Background: Though Black men with prostate cancer are more likely to have aggressive disease features than White men, race-specific differences in initial treatment responses in localized disease remains unknown. Methods: Individual patient data were obtained for 9259 patients (including 1674 [18.1%] Black men and 7585 [81.9%] White men) enrolled on eight randomized controlled trials evaluating definitive radiotherapy (RT) ± short-term or long-term androgen deprivation therapy (STADT and LTADT). The primary endpoints were biochemical recurrence (BCR), distant metastasis (DM), and prostate cancer-specific mortality (PCSM). Fine-Gray subdistribution HR (sHR) models were developed to evaluate the cumulative incidences of all endpoints after stratification by National Comprehensive Cancer Network risk grouping. A meta-analysis was done to estimate pair-wise comparisons of treatments within and between Black and White men, after adjusting for age, Gleason score, clinical T stage, and initial PSA. Results: Black men were more likely to have NCCN high-risk disease at enrollment (656/1674 [39.2%] vs 2506/7585 [33%], p<0.001). However, within the high-risk stratum Black men had lower 10-year rates of BCR (46.1% vs. 50.4%, p=0.02), DM (14% vs. 21.6%, p<0.001), and PCSM (4.9% vs. 9.8%, p<0.001). After adjusting for age and disease characteristics, Black men with high-risk prostate receiving RT+STADT had lower rates of BCR (sHR 0.73, 95% CI 0.62-0.86, p<0.001), DM (sHR 0.64, 95% CI 0.49-0.84, p=0.001) and PCSM (sHR 0.49, 95% CI 0.25-0.95, p=0.04). There were no differences in BCR, DM, or PCSM among men receiving RT+LTADT. The interaction between race and the impact of adding STADT to RT alone on BCR was statistically significant (p=0.003). Conclusions: Black men enrolled on randomized trials with long-term follow-up have higher risk disease at enrollment, but have better BCR, DM, and PCSM outcomes with RT-based therapy compared with White men, particularly with the addition of STADT.
Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial.
Feng, Felix Y. , Huang, Huei–Chung, Simko, Jeffry, Dignam, James J., Seiferheld, Wendy, Lukka, Himanshu, Bahary, Jean-Paul , Pisansky, Thomas M. , Hall, William A. , Shah, Amit I., Pugh, Stephanie L. , Pollack, Alan , Shipley, William U. , Sandler, Howard M. , Davicioni, Elai , Nguyen, Paul L. , Efstathiou, Jason A. , Dicker, Adam P. , Spratt, Daniel E. , Tran, Phuoc T

Mayo Clinic

Journal of Clinical Oncology | February 19, 2020 | Volume: 38 | Issue: 6_suppl | Pages: 276-276

10.1200/jco.2020.38.6_suppl.276 Get It

276 Background: Decipher is a genomic classifier (GC) that estimates risk of prostate cancer (PCa) distant metastases (DM) post-radical prostatectomy (RP). Herein, we validate the GC within the context of a randomized phase 3 trial. Methods: RP specimens from patients on the NRG/RTOG 9601 phase 3 placebo-controlled randomized trial of salvage radiotherapy (sRT) +/- 2 years of bicalutamide (NCT00002874) were centrally reviewed and the highest-grade tumor underwent RNA extraction. Samples passing quality control (QC) were run on a clinical-grade whole-transcriptome assay to assign the GC score (scale 0-1). Our NCTN-CCSC approved pre-specified statistical plan (NRG-GU-TS002 CSC0075) included the primary objective of validating the ability of the GC to independently prognosticate the cumulative incidence of DM, with secondary endpoints of prostate cancer-specific mortality (PCSM) and overall survival (OS). Results: Of patients with tissue available, 352 passed QC and were included for analysis. The final GC cohort was a representative sample of the overall cohort, with a median follow-up of 13 years. On multivariable analysis, the GC (continuous variable) was independently associated with DM (HR 1.19 [95%CI 1.06-1.35], p=0.003), PCSM (HR 1.37 [95%CI 1.18-1.61], p<0.001), and OS (HR 1.16 [95%CI 1.06-1.28], p=0.002) after adjusting for age, race, Gleason score, T-stage, margin status, entry PSA, and treatment arm. The estimated absolute impact of bicalutamide on 12-year OS was less in patients with lower vs higher GC scores (2.4% vs 8.9%), further demonstrated in men receiving early sRT at PSA <0.7 ng/mL (-2.0% vs 5.0%). Conclusions: This is the first validation of this GC in a prospective randomized trial cohort and demonstrates association of the GC with DM and PCSM independent of standard clinicopathologic variables. The GC may help personalize shared decision-making to weigh the absolute benefit from the addition of bicalutamide to sRT.
Impact of initial treatment selection on clinical outcomes after biochemical failure in radiorecurrent high-risk prostate cancer.
Levin-Epstein, Rebecca , Romero, Tahmineh , Wong, J.K. , Demanes, D. Jeffrey, Stish, B.J., Krauss, Daniel , Wedde, Trude B. , Lilleby, Wolfgang , Stock, Richard G. , Steinberg, Michael L. , Horwitz, Eric M. , Tendulkar, Rahul D. , Kishan, Amar U. , Cook, Kiri A. , Dess, Robert T. , Spratt, Daniel E. , Moran, Brian Joseph , Merrick, Gregory Stephen , Tran, Phuoc T , Tward, Jonathan D.

Mayo Clinic

Journal of Clinical Oncology | February 19, 2020 | Volume: 38 | Issue: 6_suppl | Pages: 208-208

10.1200/jco.2020.38.6_suppl.208 Get It

208 Background: Treatment of high risk prostate cancer (HRPCa) with external beam radiotherapy (EBRT) plus brachytherapy (BT) boost (EBRT+BT) has been prospectively associated with lower rates of BCR, albeit potentially with increased toxicity, and retrospectively linked to decreased distant metastasis (DM) and PCa-specific mortality (PCSM) compared to EBRT alone. However, it is unclear whether patients who develop BCR following either approach have similar downstream oncologic outcomes. Methods: We identified 706 out of 3820 men with HRPCa treated at 13 institutions from 1998-2015 with EBRT (n=468/2134) or EBRT+BT (n=238/1686) who developed BCR. We compared rates of DM, PCSM, and all-cause mortality (ACM) after BCR between treatment groups using Fine-Gray competing risk regression. Models were adjusted for age, Gleason grade group, initial PSA (iPSA), clinical T stage, time-dependent use of systemic salvage, and interval to BCR using inverse probability of treatment weighting. Results: Median follow-up was 9.9 years from RT and 4.8 years from BCR. Groups were similar in age, iPSA, presence of ≥2 HR features, and median interval to BCR (3.3 years). Most men received neoadjuvant/concurrent androgen deprivation therapy (ADT), 92.5% and 91.0% for EBRT and EBRT+BT, respectively, though for a longer duration with EBRT (median 14.7 vs. 9.0 months, p=0.0012). Local and systemic salvage rates were 2.3% and 36.3% after EBRT, and 2.6% and 43.6% after EBRT+BT, respectively. Initial EBRT+BT was associated with significantly lower rates of DM after BCR (HR 0.48, 95% CI 0.36-0.64, p<0.001). Rates of PCSM and ACM did not significantly differ (HR 0.93, 95% CI 0.67-1.30, p=0.93, and HR 0.8, 95% CI 0.6-1.1, p=0.11, respectively). Conclusions: In this large retrospective series of radiorecurrent HRPCa, initial treatment with EBRT+BT was associated with significantly lower rates of DM after BCR compared with EBRT, despite shorter ADT use and a similar median interval to BCR. Local salvage was widely underutilized in both groups. In the absence of salvage for local failure after EBRT, upfront treatment intensification with BT may reduce DM, though not PCSM or ACM, even after development of BCR.
Phase II trial of trifluridine/tipiracil and irinotecan for the treatment of advanced refractory biliary tract cancer.
Xie, Hao , Ahn, Daniel H. , Pitot, Henry C., Huebner, Lucas J. , Wessling, Jaclynn, Durgin, Lori, Liu, Minetta C. , Hogenson, Tara L. , Phillips, William J. , Fernández-Zapico, Martín E. , Borad, Mitesh J. , Bekaii‐Saab, Tanios , Tran, Nguyen H. , Jin, Zhaohui , Shi, Qian , Alberts, Steven R. , Mahipal, Amit

Mayo Clinic

Journal of Clinical Oncology | February 4, 2020 | Volume: 38 | Issue: 4_suppl | Pages: TPS594-TPS594

10.1200/jco.2020.38.4_suppl.tps594 Get It

TPS594 Background: Effective treatment options are very limited for patients with advanced refractory biliary tract cancer (BTC). Fluoropyrimidine-based chemotherapy regimen such as 5-fluorouracil and irinotecan are frequently utilized for these patients after first-line therapy despite lack of FDA approval. Trifluridine/tipiracil (FTD/TPI) is a novel oral nucleoside with antitumor activity in both fluoropyrimidine sensitive and resistant tumors due to its unique mechanisms of action. Given early toxicity and efficacy data from our previous study on single-agent trifluridine/tipiracil (FTD/TPI) in advanced BTC, the clinical evaluation of its combination with irinotecan represents a rational approach for the treatment of advanced refractory BTC. Methods: This is a single-arm phase II trial with a two-stage design to assess the efficacy of trifluridine/tipiracil (FTD/TPI) and irinotecan in advanced refractory BTC. Key eligibility criteria include histologically confirmed advanced, unresectable BTC who have progressed on at least one line of systemic therapy and have measurable disease per RECIST v1.1. Target accrual is 25. Treatment includes trifluridine/tipiracil (FTD/TPI) 25 mg/m2 on days 1-5 and irinotecan 180 mg/m2 on day 1 in 14-day cycles. Patients will be evaluated for response every 4 cycles and in the absence of disease progression, therapy may be given up to 2 years. The primary end point is the progression-free survival rate at 16 weeks. Secondary endpoints include overall response rate, disease control rate, progression-free survival, overall survival, and incidence of adverse events. Correlative biomarker studies include evaluations of circulating tumor DNA and circulating tumor cells at baseline, after 4 cycles and at progression; and development of patient-derived tumor organoids from pre-treatment biopsies for parallel treatments. This study was approved and funded in part by the National Comprehensive Cancer Network (NCCN) Oncology Research Program from general research support provided by Taiho Oncology, Inc. Clinical trial information: NCT 04072445.
Point-of-care 3D body-mapping for determining total body surface area of severely burned patients
Loegering, Julia, Krause, Kevin, Ahlquist, Jesse , Webb, Kevin, Xu, Karen , Greenhalgh, David , Palmieri, Tina L. , Webb, Kevin L., Tran, Nam K , Greenhalgh, David

Mayo Clinic

2019 IEEE Healthcare Innovations and Point of Care Technologies, (HI-POCT) | January 21, 2020 | Volume: No volume available | Issue: No issue available | Pages: 111-114

10.1109/hi-poct45284.2019.8962792 Get It